Key Points
- CEO Raju Mohan sold 47,345 shares at an average price of $7.72 on Dec. 18 for $365,503, reducing his position by 1.96% to 2,372,863 shares (about $18.32M); the sale was disclosed in an SEC filing.
- Ventyx stock climbed 12.9% and opened at $8.74; the company has a market cap of $623.7M, a 52‑week range of $0.78–$10.55, and 50/200‑day SMAs of $7.90 and $4.49.
- Analysts have been raising targets and ratings — four Buys and one Sell — giving an average price target of $15.50, with recent upgrades and higher targets from Wells Fargo, Oppenheimer, Canaccord and HC Wainwright.
Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) insider John Nuss sold 12,675 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider directly owned 489,481 shares of the company's stock, valued at $3,778,793.32. This trade represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Ventyx Biosciences Stock Performance
Shares of NASDAQ VTYX opened at $8.74 on Friday. The business has a 50 day simple moving average of $7.90 and a 200 day simple moving average of $4.49. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $10.55. The stock has a market cap of $623.69 million, a price-to-earnings ratio of -5.83 and a beta of 1.22.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. On average, analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.
Hedge Funds Weigh In On Ventyx Biosciences
A number of institutional investors have recently made changes to their positions in VTYX. Hudson Bay Capital Management LP bought a new stake in Ventyx Biosciences during the 2nd quarter valued at approximately $34,000. Pallas Capital Advisors LLC acquired a new position in shares of Ventyx Biosciences during the second quarter worth approximately $38,000. Engineers Gate Manager LP acquired a new position in shares of Ventyx Biosciences during the second quarter worth approximately $42,000. Persistent Asset Partners Ltd bought a new stake in shares of Ventyx Biosciences in the third quarter valued at approximately $51,000. Finally, Jump Financial LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter worth $53,000. 97.88% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
VTYX has been the subject of a number of recent research reports. Oppenheimer upped their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an "outperform" rating in a report on Monday, October 27th. Wells Fargo & Company boosted their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Canaccord Genuity Group raised their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, November 7th. Finally, HC Wainwright upgraded Ventyx Biosciences from a "neutral" rating to a "buy" rating and set a $18.00 price target on the stock in a report on Wednesday, November 5th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.50.
Check Out Our Latest Stock Report on VTYX
Ventyx Biosciences Company Profile
(
Get Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
